Meeting
2023 ASCO Annual Meeting
KEYFORM-008: Coformulated favezelimab and pembrolizumab (MK4280A) versus chemotherapy in relapsed/refractory classical Hodgkin lymphoma.
Authors
David Lavie
Hadassah Medical Center, Jerusalem, Israel
David Lavie , John Timmerman , Ramón Garcia Sanz , Won Seog Kim , Tae Min Kim , Abraham Avigdor , Daan Dierickx , Deepa Jagadeesh , Daniel Molin , Muhit Ozcan , Ömür Gökmen Sevindik , Hayder Saeed , Yulia Sidi , Pallavi Pillai , Patricia Marinello , Alex Francisco Herrera
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Hodgkin Lymphoma
Clinical Trial Registration Number
NCT05508867
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS7585)
DOI
10.1200/JCO.2023.41.16_suppl.TPS7585
Abstract #
TPS7585
Poster Bd #
132b
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Response-adapted therapy (tx) with nivolumab plus brentuximab vedotin (nivo + BV) without autologous hematopoietic cell transplantation (auto-HCT) in children, adolescents, and young adults (CAYA) with low-risk relapsed/refractory (R/R) classic Hodgkin lymphoma (cHL): CheckMate 744.
First Author: Paul David Harker-Murray
Poster
2016 ASCO Annual Meeting
Pembrolizumab for relapsed/refractory classical Hodgkin lymphoma (R/R cHL): phase 2 KEYNOTE-087 study.
First Author: Robert W. Chen
Poster
2024 ASCO Annual Meeting
The safety and efficacy of ivonescimab in combination with chemotherapy as first-line treatment for advanced biliary tract cancer.
First Author: Jieer Ying
Poster
2024 ASCO Annual Meeting
A phase II trial to assess the impact of β2 adrenergic blockade in immune checkpoint inhibitor (ICI)– refractory metastatic triple negative breast cancer (mTNBC).
First Author: Shipra Gandhi